Recombinant human IGF-1 is used to treat severe primary IGF-1 deficiency, but this treatment requires twice-daily injection, often does not fully correct the growth deficit, and has important off-target effects. The gene discussed is IGF1; the disease is hyperinsulinemic hypoglycemia, familial, 4.